key: cord-1003487-260xsb7x authors: Chang, Xinyue; Augusto, Gilles Sousa; Liu, Xuelan; Kündig, Thomas M; Vogel, Monique; Mohsen, Mona O.; Bachmann, Martin F. title: BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant viruses is up to 10-fold reduced date: 2021-03-15 journal: bioRxiv DOI: 10.1101/2021.03.13.435222 sha: 7e8a8108b4e051b068eb2aa4b4148df63cdbffc4 doc_id: 1003487 cord_uid: 260xsb7x Background Several new variants of SARS-CoV-2 have emerged since fall 2020 which have multiple mutations in the receptor binding domain (RBD) of the spike protein. Objective We aimed to assess how mutations in RBD affected recognition of immune sera by antibodies induced by natural infection versus immunization with BNT162b2, a mRNA-based vaccine against COVID-19. Methods We produced SARS-CoV-2 RBD mutants with single mutations in the receptor binding domain (RBD) region (E484K, K417N, N501Y) or with all 3 mutations combined, as occurring in the newly emerged variants B.1.351 (South Africa) and P.1 (Brazil). Using standard and avidity ELISAs, we determined the binding capacities to mutant RBDs of antibodies induced by infection versus vaccination. Results These binding assays showed that vaccination induced antibodies recognize both wildtype and mutant RBDs with higher avidities than those raised by infection. Nevertheless, recognition of mutants RBDK417N and RBDN501Y was 2.5-3-fold reduced while RBDE484K and the triple mutant were 10-fold less well recognized, demonstrating that the mutation at position 484 was key for the observed loss in cross-reactivity. Conclusion Our binding data demonstrate improved recognition of mutant viruses by BNT162b2-induced antibodies compared to those induced by natural infection. Recognition may, however, be 10-fold reduced for the variants B.1.351/P.1, suggesting that the development of a new vaccine is warranted. The E484K mutation is an key hurdle for immune recognition, convalescent plasma and monoclonal antibody therapy as well as serological assays based on the wildtype sequence may therefore seriously impaired. Capsule summary BNT162b2 mRNA COVID-19 vaccine-induced antibodies recognize mutant viruses with up to 10-fold lower efficiency Because of its critical role in virus attachment and cell entry, the receptor biding domain (RBD) of SARS-CoV-2 spike (S) glycoprotein is the primary target for neutralizing antibodies protective against COVID-19 1, 2 . In this context, it has been shown that ELISA titers against RBD correlate tightly with virus neutralization 3 . It has also been demonstrated that antibody responses induced by immunization against full-length S or parts of it may result in more potent and longer-lasting responses than those elicited by natural infection with the virus 4 . These data corroborate the consensus that global vaccination programs are the most promising strategy for controlling the present COVID-19 pandemic. A worrying factor, however, has been the emergence of variants with the ability to escape immunity produced by vaccination, potentially frustrating the unprecedented efforts to quickly A previous study showed that serum neutralization is not compromised by N501Y (also found in the UK strain B.1.1.7) 7 . In contrast, E484K (found in the South Africa 501Y.V2 and in the Brazilian P.1 strains) was associated with reduced neutralization 8, 9 . Interestingly, studies applying in vitro pressure produced similar mutations as those that occurred naturally 10 . Whether reduced neutralization was due to impaired binding was, however, not analyzed. Here we assessed the presence of such cross-reactive antibodies in convalescent sera and sera from individuals immunized with mRNA-based BNT162b2 vaccine. In order to analyze cross-reactive binding of antibodies induced by infection or vaccination, we generated four mutant RBDs (RBD mutant K417N (RBD417) RBD mutant E484K (RBD484), RBD mutant N501Y (RBD501) and an RBD version mutated at all three sites (RBDtrip) (Fig 1A) . Please note that 2 mutations, E484K, N501Y, are localized within the receptor binding motif (RBM) 11 , directly interacting with ACE2. The domains were expressed eukaryotically in 293 cells followed by purification via HIS-tag. To assess the ability of antibodies induced by vaccination or infection to bind the different mutant RBDs, ELISAs were performed using sera from 11 convalescent patients or 6 individuals immunized with BNT162b2 (day 0 and day 21; blood was taken 2 weeks after the second dose). Our data show that binding of convalescent sera was strongly reduced for RBD417 and RBD501 and essentially abolished for RBD484 and RBDtrip ( Fig 1B, left panel) . In contrast, BNT162b2 induced antibodies exhibited only weakly reduced binding to RBD417 and RBD501 (2.5-3-fold), but binding was 10-fold reduced to RBD484 and RBDtrip (Fig 1B, right panel) . Figure 1C summarizes the antibody titers and Figure 1D quantifies the reduced binding of vaccine induced sera to the mutant RBDs compared to wild type RBD. It is interesting to note that the single mutation E484K was equally potent at reducing antibody binding as all three mutants together in RBDtrip, indicating that the mutation E484K is particularly problematic, perhaps because it involves a change from positive to negative charge. In order to estimate the avidity of the 2 types of antibodies for RBD and the mutants, we performed avidity assays. To this end, ELISAs were performed with an additional washing step with 7M urea and OD50 values were compared to plates washed with PBS only. Interestingly, virus-induced antibodies were of limited avidity for wild-type RBD, and binding to mutant RBDs was essentially abolished if plates were washed with 7M urea, indicating that the antibodies that bound to the mutant RBDs were all of low avidity (Fig 2A shows results for RBDwt). In contrast, BNT162b2 induced antibodies were of significantly higher avidity than infection induced antibodies (Fig 2B) . In addition, there was some residual binding to the mutant RBDs, 7 indicating, however, overall low avidity as well (see below). The avidity index allows to quantify the loss in binding induced by the 7M urea wash and therefore reflect the "quality" of the antibodies. Indeed, the avidity of vaccine-induced antibodies is much higher for RBD and the mutants than those induced by infection (Fig 2C) . This reduced affinity of antibodies induced by infection is consistent with the notion that individual RBDs are spaced by 25 nm on SARS-CoV-2, too large a distance for induction of optimal antibodies 12 . A key question for serology will be to see whether absence of cross-reactivity of convalescent sera holds true for individuals infected by mutant strains at position 484. This would need revision of all RBD-based serological assays. The SARS-CoV-2 receptor-binding domain (RBDwt) and the RBD mutant (RBD417, RBD501, RBD484 and RBDtrip) were expressed using Expi293F cells (Invitrogen, ThermoFisher Scientific, MA, USA). The genes that encode SARS-CoV-2 RBDwt (residues Arg319-Phe541) or RBD mutants with a C-terminal 6-His-tag was inserted into pTwist CMV BetaGlobin WPRE Neo vector (Twist Bioscience, San Francisco, USA). The construct plasmids were amplified in E. coli XL-1 Blue electrocompetent cells, and were then transfected into Expi293F cells at a density of 3×10 6 cells/ml using ExpiFectatmine 293 transfection kit (Gibco, ThermoFisher Scientific, MA, USA). The supernatant of cell culture containing the secreted RBDs was harvested 96 h after infection, and purified by passing His-Trap HP column (GE Healthcare, USA). Collected RBDs proteins were equilibrated in PBS and kept at -20˚C. Human sera were obtained from 11 COVID-19 convalescent patients and from 6 individuals immunized twice (days 0 and 21) with BNT162b2 according to standard protocols 13 . Sera of immunized individuals were taken 14 days after second vaccine injection. Corning half area 96-well plates were coated with 1 µg/ml RBDwt or mutated RBDs in PBS overnight at 4°C. Then plates were blocked for 2 hours at room temperature with PBS-0.15% Casein. Afterwards, convalescent human sera, BNT162b2 immunized human sera were added, serially diluted 1:3 and incubated on plates for one hour at room temperature. Bound IgG antibodies were detected with goat anti-human IgG-POX antibody (Nordic MUbio, Susteren, The Netherlands). ELISA was developed with tetramethylbenzidine (TMB), stopped by adding equal 1 M H2SO4 solution, and read at OD450nm. To determine the avidity of IgG antibodies, two sets of plates were prepared. Both are coated with 1 µg/ml RBDs, and after incubation with serial serum dilutions, one set of plates was washed three times for 3 minutes with 50 µl/well 7M Urea in PBS+0.05% Tween 20 whereas the other set was washed with the same amount of PBS+0.05% Tween. In-between the washing steps, all the plates were washed with PBS+0.01% Tween 20 (PBST) with the ELISA washer (BioTek, Sursee, Switzerland). The rest of the procedure is identical as described 11 above. Avidity indexes were calculated as the fraction of the area under the curve washed with PBST versus those washed with urea. All statistical tests were performed using GraphPad PRISM 6.0 (GraphPad Software, Inc.). ELISA data in graphs are displayed as OD450 values of individual mice ± SEM. Comparison between RBDwt and mutated RBDs were analyzed by paired two-tailed Student's t-test. α=0.05 and statistical significance are displayed as p≤0.05 (*), p≤0.01 (**), p≤0.005 (***), p≤0.001 (****). Correlates of protection induced by vaccination A natural mutation between SARS-CoV-2 and SARS-CoVdetermines neutralization by a cross-reactive antibody Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study The trinity of COVID-19: immunity, inflammation and intervention Human neutralizing antibodies elicited by SARS-CoV-2 infection Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings SARS-CoV-2 structural features may explain limited neutralizing-antibody responses Safety and efficacy of the BCT162b2 mRNA Covid-19 Vaccine We thank Marianne Zwicker for production of mutant RBDs.